This presented was delivered to the Licensing Industry Merchandisers’ Association at the Advanced Licensing Seminar.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...